Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent may reveal hidden lung scars in COVID survivors

NCT ID NCT04376593

Knowledge-focused Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a radioactive tracer called 18F-αvβ6-BP in 5 people who had recovered from COVID-19. The goal was to see if the tracer could highlight lung damage on PET/CT scans. Participants received the tracer intravenously and underwent imaging. The study only assessed whether the tracer could be given safely and whether it accumulated in areas of lung injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-αvβ6-binding-peptide (a radioactive tracer for PET scans)
What this could lead to
If successful, this imaging method could help doctors see lung damage from COVID-19 more clearly, potentially guiding treatment decisions.
What could go wrong
This is a very early, tiny study (5 people) that only tests whether the tracer can be given safely and shows up in the lungs. It does not test any treatment or long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

5 people

The number who actually took part.

Started

May 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women age ≥ 18 yrs * Diagnosed with SARS CoV2 * Must have 2 sequential COVID negative tests prior to each scan * Must have no previous lung disease prior to SARS CoV2 infection * Lung image (Xray or CT) taken during infectious/ diagnosis period * Will sign the IRB-approved consent form * Able to remain motionless for up to 30-60 minutes per scan. Exclusion Criteria: * Life expectancy \<3 mo * Women who are pregnant or breast-feeding * Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs) * Lack of availability for follow-up assessments * Re-infection with SARS CoV2 between scan sessions * Other active infectious respiratory illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19 SARS-CoV-2 infection

Contacts and locations

Locations

  • University of California Davis

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.